Source: Eur Respir J 2013; 42: 1003-1011
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Dasgupta Angira, Zhang Shiyuan, Thabane Lehana, Nair Parameswaran. Sample sizes for clinical trials using sputum eosinophils as a primary outcome. Eur Respir J 2013; 42: 1003-1011

Member's Comments

No comment yet.

Related content which might interest you: The use of induced sputum in clinical trials Source: Eur Respir J 2002; 20: 47S-50S Year: 2002 Asthma treatment based on sputum cell counts or usual clinical outcomes: the LOMA study Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003 Missing sputum samples are common in asthma intervention studies and successful collection at follow-up is related to improvement in clinical outcomes Source: ERJ Open Res, 8 (1) 00612-2021; 10.1183/23120541.00612-2021 Year: 2022 Induced sputum: standardisation of methods and cell counts in a multi-centre trial Source: Eur Respir J 2003; 22: Suppl. 45, 412s Year: 2003 Relative sensitivity of markers of activated eosinophils in clinical trials for asthma Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 Heterogeneity of treatment response in bronchiectasis clinical trials Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Blood eosinophils in COPD: long term variability and clinical outcomes Source: International Congress 2017 – Innovation in COPD: techniques and facts Year: 2017 Associations between blood and sputum eosinophils and clinical features of mild-to-moderate COPD Source: International Congress 2019 – Airway diseases and blood cells Year: 2019 The effect of azithromycin on sputum inflammatory markers in bronchiectasis – analysis of a randomized controlled trial Source: International Congress 2019 – Advances in bronchiectasis and non-TB mycobacterial infections Year: 2019 Comparison of sputum characteristics with clinical, laboratorial and functional variables in patients with stable COPD Source: Annual Congress 2010 - Colonisation and infection in COPD Year: 2010 Clinical and inflammatory characteristics of patients with COPD in primary care: an observational study Source: International Congress 2017 – Markers of COPD progression Year: 2017 Methodology of clinical trials in COPD exacerbations: Eligibility criteria and endpoint selection. Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Yield of examining repeated sputum specimens in diagnosis of pulmonary tuberculosis: how many sputum samples are adequate? Source: Eur Respir J 2004; 24: Suppl. 48, 33s Year: 2004 The effect of heparin nebulization on BAL cellularity and clinical evaluation in a long-time study in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 373s Year: 2002 The value of BAL in the assessment of pulmonary sarcoidosis in clinical practice: a retrospective analysis Source: Eur Respir J 2001; 18: Suppl. 33, 68s Year: 2001 Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial Source: Eur Respir J, 51 (4) 1701389; 10.1183/13993003.01389-2017 Year: 2018 Publication rate and characteristics of industry-sponsored asthma clinical trials Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020 Sputum induction in asthmatic children: safety in children and feasibility of new methods of monitoring inflammation in sputum samples Source: Eur Respir J 2006; 28: Suppl. 50, 259s Year: 2006 Safety of sputum induction in asthmatics in clinical practice Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010